Arcus Biosciences, Inc.
RCUS Mid CapHealthcare · Biotechnology
Updated: Jun 14, 2026, 22:19 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clini
Arcus Biosciences, Inc. Stock at a Glance
Arcus Biosciences, Inc. (RCUS) is currently trading at $23.80 with a market capitalization of $3B. The 52-week range spans from $7.91 to $28.72; the current price is 17.1% below the yearly high. Year-over-year revenue growth stands at -39.3%.
💰 Dividend
Arcus Biosciences, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
12 analysts rate Arcus Biosciences, Inc. (RCUS) on consensus: Strong Buy. The average price target is $35.75, implying +50.21% from the current price. Analyst price targets range from $22.00 to $47.00.
Arcus Biosciences, Inc.: The Investment Case in Detail
Arcus Biosciences, Inc. (RCUS) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Wall Street consensus sits at Strong Buy with an average price target implying roughly 50.21% upside from current levels — analyst sentiment is firmly constructive.
The Bear Case
Revenue is contracting at -39.3% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 15.32% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
What to Watch Next
- The analyst consensus price target implies 50.21% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Investment Thesis: Strengths & Weaknesses
- Analyst consensus: Strong Buy
- Solid balance sheet with low debt (D/E 21.57)
- –Revenue shrinking (-39.3% YoY)
- –Currently unprofitable
- –High short interest (15.32%)
- –Negative free cash flow
Technical Snapshot
Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).
Risk Profile
The data points to relatively defensive market behavior, elevated short interest (15.32%).
Trading Data
Related Stocks in the Same Sector
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Arcus Biosciences, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news